

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**UNIVERSITY RX SPECIALIST,
DBA UNIVERSITY COMPOUNDING
PHARMACY
1875 3RD Avenue
San Diego, CA 92101**

**Pharmacy Permit No. PHY 45621
Sterile Compounding License No. LSC 99018**

**JOSEPH GRASELA
4767 Ocean Blvd., #1001
San Diego, CA 92109**

Pharmacist License No. RPH 40868

Case No. 4347

OAH No. 2015020529

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER**

Respondents.

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on April 1, 2016.

It is so ORDERED on March 2, 2016.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

Amy Gutierrez, Pharm.D.
Board President

1 KAMALA D. HARRIS
Attorney General of California
2 GREGORY J. SALUTE
Supervising Deputy Attorney General
3 DESIREE I. KELLOGG
Deputy Attorney General
4 State Bar No. 126461
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 645-2996
7 Facsimile: (619) 645-2061
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:

Case No. 4347

12 **UNIVERSITY RX SPECIALIST,**
13 **DBA UNIVERSITY COMPOUNDING**
14 **PHARMACY 1875 3rd Avenue**
San Diego, CA 92101

OAH No. 2015020529

15 **Pharmacy Permit No. PHY 45621**
16 **Sterile Compounding License No. LSC**
99018

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER

17 **and**

18 **JOSEPH GRASELA**
19 **4767 Ocean Blvd., #1001**
San Diego, CA 92109

20 **Pharmacist License No. RPH 40868**

21 Respondents.
22

23 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
24 entitled proceedings that the following matters are true:

25 **PARTIES**

26 1. Virginia Herold ("Complainant") is the Executive Officer of the Board of Pharmacy.
27 She brought this action solely in her official capacity and is represented in this matter by Kamala
28

1 D. Harris, Attorney General of the State of California, by Desiree I. Kellogg, Deputy Attorney
2 General.

3 2. Respondents University RX Specialist, dba University Compounding Pharmacy and
4 Joseph Grasela ("Respondents") are represented in this proceeding by attorney Tony J. Park,
5 Pharm.D., J.D., whose address is: 2855 Michelle Drive, Suite 180, Irvine, CA, 92606-1027.

6 3. On or about March 31, 1987, the Board of Pharmacy issued Pharmacist License No.
7 RPH 40868 to Joseph Grasela (Respondent Joseph Grasela). The Pharmacist License was in full
8 force and effect at all times relevant to the charges brought in Accusation No. 4347 and will
9 expire on November 30, 2016, unless renewed.

10 4. On or about August 23, 2002, the Board of Pharmacy issued Pharmacy Permit
11 Number PHY 45621 to University RX Specialist, doing business as University Compounding
12 Pharmacy (Respondent UCP) with Joseph Grasela as the President and Pharmacist-in-Charge.
13 The Pharmacy Permit was in full force and effect at all times relevant to the charges brought in
14 Accusation No. 4347 and will expire on August 1, 2016, unless renewed.

15 5. On or about July 1, 2003, the Board of Pharmacy issued Sterile Compounding
16 License Number LSC 99018 to University RX Specialist, doing business as University
17 Compounding Pharmacy (Respondent UCP). The Sterile Compounding License was in full force
18 and effect at all times relevant to the charges brought in Accusation No. 4347 and will expire on
19 August 1, 2016, unless renewed.

20 JURISDICTION

21 6. Accusation No. 4347 was filed before the Board of Pharmacy (Board), Department of
22 Consumer Affairs, and is currently pending against Respondents. The Accusation and all other
23 statutorily required documents were properly served on Respondents on January 15, 2015.
24 Respondents timely filed its Notice of Defense contesting the Accusation. The Board filed First
25 Amended Accusation on November 20, 2015.

26 7. A copy of First Amended Accusation No. 4347 is attached as exhibit A and
27 incorporated herein by reference.
28

ADVISEMENT AND WAIVERS

8. Respondents have carefully read, fully discussed with counsel, and understand the charges and allegations in First Amended Accusation No. 4347. Respondents have also carefully read, fully discussed with counsel, and understand the effects of this Stipulated Settlement and Disciplinary Order.

9. Respondents are fully aware of their legal rights in this matter, including the right to a hearing on the charges and allegations in the First Amended Accusation; the right to confront and cross-examine the witnesses against them; the right to present evidence and to testify on their own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.

10. Respondents voluntarily, knowingly, and intelligently waive and give up each and every right set forth above.

CULPABILITY

11. Respondents understand and agree that the charges and allegations in First Amended Accusation No. 4347, if proven at a hearing, constitute cause for imposing discipline upon their Pharmacist License, Pharmacy Permit, and Sterile Compounding License.

12. For the purpose of resolving the First Amended Accusation without the expense and uncertainty of further proceedings, Respondents agree that, at a hearing, Complainant could establish a factual basis for the charges in the First Amended Accusation, and that Respondents hereby give up their right to contest those charges.

13. Respondents agree that Pharmacist License No. RPH 40868, Pharmacy Permit No. PHY 45621, and Sterile Compounding License Number LSC 99018 are subject to discipline and they agree to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

CONTINGENCY

14. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondents or their counsel. By signing the stipulation, Respondents understand and agree that they may not withdraw their agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

15. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.

16. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

17. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Pharmacist License No. RPH 40868 to Joseph Grasela (Respondent Joseph Grasela), Pharmacy Permit No. PHY 45621 issued to Respondent University RX Specialist, dba University Compounding Pharmacy (Respondent UCP), and Sterile Compounding License Number LSC 99018 issued to University RX Specialist, doing business as

University Compounding Pharmacy (Respondent UCP) are revoked. However, the revocation is stayed and Respondents are placed on probation for four (4) years on the following terms and conditions.

1. Suspension

As part of probation, Respondent UCP's Sterile Compounding License Number LSC 99018 is suspended from compounding any nonsterile to sterile drug products beginning the effective date of this decision until the Board or its representative has confirmed that all nonsterile to sterile compounding performed at Respondent UCP is done in compliance with the laws and regulations.

During the period of suspension, Respondent UCP shall not compound nonsterile to sterile products or dispense to patients, nonsterile to sterile drug products compounded by UCP. Failure to comply with this suspension shall be considered a violation of probation.

On or before the effective date of this decision, the Board or its representative will make best efforts to conduct an inspection(s) of Respondent's compliance with the laws and regulations.

2. Obey All Laws

Respondents shall obey all state and federal laws and regulations.

Respondents shall report any of the following occurrences to the Board, in writing, within seventy-two (72) hours of such occurrence:

- ☐ an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- ☐ a plea of guilty or nolo contendere in any state or federal criminal proceeding to any criminal complaint, information or indictment
- ☐ a conviction of any crime
- ☐ discipline, citation, or other administrative action filed by any state or federal agency which involves Respondents' pharmacist license, pharmacy permit or sterile compounding permit or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

1 **3. Report to the Board**

2 Respondents shall report to the Board quarterly, on a schedule as directed by the Board or
3 its designee. The report shall be made either in person or in writing, as directed. Among other
4 requirements, Respondents shall state in each report under penalty of perjury whether there has
5 been compliance with all the terms and conditions of probation. Failure to submit timely reports
6 in a form as directed shall be considered a violation of probation. Any period(s) of delinquency
7 in submission of reports as directed may be added to the total period of probation. Moreover, if
8 the final probation report is not made as directed, probation shall be automatically extended until
9 such time as the final report is made and accepted by the Board.

10 **4. Interview with the Board**

11 Upon receipt of reasonable prior notice, Respondents shall appear in person for interviews
12 with the Board or its designee, at such intervals and locations as are determined by the Board or
13 its designee. Failure to appear for any scheduled interview without prior notification to Board
14 staff, or failure to appear for two (2) or more scheduled interviews with the Board or its designee
15 during the period of probation, shall be considered a violation of probation.

16 **5. Cooperate with Board Staff**

17 Respondents shall cooperate with the Board's inspection program and with the Board's
18 monitoring and investigation of respondent's compliance with the terms and conditions of their
19 probation. Failure to cooperate shall be considered a violation of probation.

20 **6. Reimbursement of Board Costs**

21 As a condition precedent to successful completion of probation, Respondents shall pay to
22 the Board its costs of investigation and prosecution in the amount of \$20,000.00. Respondents
23 shall be jointly and severally liable for payment of these costs. Commencing on the effective date
24 of this Decision, Respondents shall make payments of \$1,000.00 per month until paid in full.

25 There shall be no deviation from this schedule absent prior written approval by the Board or
26 its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of
27 probation.
28

1 The filing of bankruptcy by Respondents shall not relieve Respondents of their
2 responsibility to reimburse the Board its costs of investigation and prosecution.

3 **7. Probation Monitoring Costs**

4 Respondents shall pay any costs associated with probation monitoring as determined by the
5 Board each and every year of probation. Such costs shall be payable to the Board on a schedule
6 as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as directed
7 shall be considered a violation of probation.

8 **8. Status of License**

9 Respondents shall, at all times while on probation, maintain current licensure with the
10 Board. Failure to maintain active, current licenses shall be considered a violation of probation.

11 If Respondent UCP submits an application to the Board, and the application is approved,
12 for a change of location, change of permit or change of ownership, the Board shall retain
13 continuing jurisdiction over the license, and Respondent UCP shall remain on probation as
14 determined by the Board.

15 If Respondents' licenses expire or are cancelled by operation of law or otherwise at any
16 time during the period of probation, including any extensions thereof due to tolling or otherwise,
17 upon renewal or reapplication Respondents' licenses shall be subject to all terms and conditions
18 of this probation not previously satisfied.

19 **9. Pharmacy Permit Surrender While on Probation/Suspension**

20 Following the effective date of this decision, should Respondent UCP discontinue business,
21 Respondents may tender the premises license to the Board for surrender. The Board or its
22 designee shall have the discretion whether to grant the request for surrender or take any other
23 action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the
24 license, Respondent UCP will no longer be subject to the terms and conditions of probation.

25 Upon acceptance of the surrender, Respondent owner shall relinquish the premises wall and
26 renewal license to the Board within ten (10) days of notification by the Board that the surrender is
27 accepted. Respondent owner shall further submit a completed Discontinuance of Business form
28 according to Board guidelines and shall notify the Board of the records inventory transfer.

Respondent owner shall also, by the effective date of this decision, arrange for the continuation of care for ongoing patients of the pharmacy by, at minimum, providing a written notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that identifies one or more area pharmacies capable of taking up the patients' care, and by cooperating as may be necessary in the transfer of records or prescriptions for ongoing patients. Within five days of its provision to the pharmacy's ongoing patients, Respondent owner shall provide a copy of the written notice to the Board. For the purposes of this provision, "ongoing patients" means those patients for whom the pharmacy has on file a prescription with one or more refills outstanding, or for whom the pharmacy has filled a prescription within the preceding sixty (60) days.

Respondent owner may not apply for any new licensure from the Board for three (3) years from the effective date of the surrender. Respondent owner shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the Board.

Respondent owner further stipulates that he or she shall reimburse the Board for its costs of investigation and prosecution prior to the acceptance of the surrender.

10. Pharmacist License Surrender While on Probation/Suspension

Following the effective date of this decision, should Respondent Joseph Grasela cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, Respondent Joseph Grasela may tender his Pharmacist License to the Board for surrender. The Board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, Respondent Joseph Grasela will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the Respondent Joseph Grasela's license history with the Board.

Upon acceptance of the surrender, Respondent Joseph Grasela shall relinquish his pocket and wall license to the Board within ten (10) days of notification by the Board that the surrender is accepted. Respondent Joseph Grasela may not reapply for any license from the Board for three (3) years from the effective date of the surrender. Respondent Joseph Grasela shall meet all

requirements applicable to the license sought as of the date the application for that license is submitted to the Board, including any outstanding costs.

11. Notice to Employees

Respondent UCP shall, upon or before the effective date of this decision, ensure that all employees involved in permit operations are made aware of all the terms and conditions of probation, either by posting a notice of the terms and conditions, circulating such notice, or both. If the notice required by this provision is posted, it shall be posted in a prominent place and shall remain posted throughout the probation period. Respondent owner shall ensure that any employees hired or used after the effective date of this decision are made aware of the terms and conditions of probation by posting a notice, circulating a notice, or both. Additionally, respondent owner shall submit written notification to the Board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to submit such notification to the Board shall be considered a violation of probation.

"Employees" as used in this provision includes all full-time, part-time, volunteer, temporary and relief employees and independent contractors employed or hired at any time during probation.

12. Owners and Officers: Knowledge of the Law

Respondent UCP shall provide, within thirty (30) days after the effective date of this decision, signed and dated statements from its owners, including any owner or holder of ten percent (10%) or more of the interest in Respondent or Respondent's stock, and any officer, stating under penalty of perjury that said individuals have read and are familiar with state and federal laws and regulations governing the practice of pharmacy. The failure to timely provide said statements under penalty of perjury shall be considered a violation of probation.

13. Posted Notice of Probation

Respondent UCP shall prominently post a probation notice provided by the Board in a place conspicuous and readable to the public. The probation notice shall remain posted during the entire period of probation.

1 Respondent owner shall not, directly or indirectly, engage in any conduct or make any
2 statement which is intended to mislead or is likely to have the effect of misleading any patient,
3 customer, member of the public, or other person(s) as to the nature of and reason for the probation
4 of the licensed entity.

5 Failure to post such notice shall be considered a violation of probation.

6 **14. Violation of Probation**

7 If Respondents have not complied with any term or condition of probation, the Board shall
8 have continuing jurisdiction over Respondents' licenses, and probation shall be automatically
9 extended until all terms and conditions have been satisfied or the Board has taken other action as
10 deemed appropriate to treat the failure to comply as a violation of probation, to terminate
11 probation, and to impose the penalty that was stayed.

12 If Respondents violate probation in any respect, the Board, after giving Respondents notice
13 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that
14 was stayed. Notice and opportunity to be heard are not required for those provisions stating that a
15 violation thereof may lead to automatic termination of the stay and/or revocation of the license. If
16 a petition to revoke probation or an accusation is filed against Respondents during probation, the
17 Board shall have continuing jurisdiction and the period of probation shall be automatically
18 extended until the petition to revoke probation or accusation is heard and decided.

19 **15. Completion of Probation**

20 Upon written notice by the Board or its designee indicating successful completion of
21 probation, Respondents' licenses will be fully restored.

22 **16. Continuing Education**

23 Respondent Joseph Grasela shall provide evidence of efforts to maintain skill and
24 knowledge as a pharmacist as directed by the Board or its designee.

25 **17. Notice to Employers**

26 During the period of probation, Respondent Joseph Grasela shall notify all present and
27 prospective employers of the decision in case number 4347 and the terms, conditions and
28 restrictions imposed on Respondent Joseph Grasela by the decision, as follows:

1 Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of
2 Respondent Joseph Grasela's undertaking any new employment, he shall cause his direct
3 supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during
4 respondent's tenure of employment) and owner to report to the Board in writing acknowledging
5 that the listed individual(s) has/have read the decision in case number 4347, and terms and
6 conditions imposed thereby. It shall be Respondent Joseph Grasela's responsibility to ensure that
7 his employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the Board.

8 If Respondent Joseph Grasela works for or is employed by or through a pharmacy
9 employment service, he must notify his direct supervisor, pharmacist-in-charge, and owner at
10 every entity licensed by the Board of the terms and conditions of the decision in case number
11 4347 in advance of the Respondent Joseph Grasela commencing work at each licensed entity. A
12 record of this notification must be provided to the board upon request.

13 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen
14 (15) days of Respondent Joseph Grasela undertaking any new employment by or through a
15 pharmacy employment service, he shall cause his direct supervisor with the pharmacy
16 employment service to report to the Board in writing acknowledging that he has read the decision
17 in case number 4347 and the terms and conditions imposed thereby. It shall be Respondent
18 Joseph Grasela's responsibility to ensure that his employer(s) and/or supervisor(s) submit timely
19 acknowledgment(s) to the Board.

20 Failure to timely notify present or prospective employer(s) or to cause that/those
21 employer(s) to submit timely acknowledgments to the Board shall be considered a violation of
22 probation.

23 "Employment" within the meaning of this provision shall include any full-time,
24 part-time, temporary, relief or pharmacy management service as a pharmacist or any
25 position for which a pharmacist license is a requirement or criterion for employment,
26 whether the respondent is an employee, independent contractor or volunteer.
27
28

18. **No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as Designated Representative-in-Charge, or Serving as a Consultant**

During the period of probation, Respondent Joseph Grasela shall not supervise any intern pharmacist, be the pharmacist-in-charge or designated representative-in-charge of any entity licensed by the Board nor serve as a consultant unless otherwise specified in this order.

Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.

19. **Notification of a Change in Name, Residence Address, Mailing Address or Employment**

Respondent Joseph Grasela shall notify the Board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule if known.

Respondent Joseph Grasela shall further notify the Board in writing within ten (10) days of a change in name, residence address, mailing address, or phone number.

Failure to timely notify the Board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

20. **Tolling of Probation**

Except during periods of suspension, Respondent Joseph Grasela shall, at all times while on probation, be employed as a pharmacist in California for a minimum of thirty (30) hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, Respondent Joseph Grasela must nonetheless comply with all terms and conditions of probation.

Should Respondent Joseph Grasela, regardless of residency, for any reason (including vacation) cease practicing as a pharmacist for a minimum of thirty (30) hours per calendar month in California, he must notify the board in writing within ten (10) days of the cessation of practice, and must further notify the board in writing within ten (10) days of the resumption of practice. Any failure to provide such notification(s) shall be considered a violation of probation.

1 It is a violation of probation for Respondent Joseph Grasela's probation to remain tolled
2 pursuant to the provisions of this condition for a total period, counting consecutive and non-
3 consecutive months, exceeding thirty-six (36) months.

4 "Cessation of practice" means any calendar month during which respondent is
5 not practicing as a pharmacist for at least thirty (30) hours, as defined by Business
6 and Professions Code section 4000 et seq. "Resumption of practice" means any
7 calendar month during which respondent is practicing as a pharmacist for at least
8 thirty (30) hours as a pharmacist as defined by Business and Professions Code section
9 4000 et seq.

10 **21. Remedial Education**

11 Within sixty (60) days of the effective date of this decision, Respondent Joseph Grasela
12 shall submit to the Board or its designee, for prior approval, an appropriate program of remedial
13 education related to compounding and legal requirements. The program of remedial education
14 shall consist of at least six (6) hours, which shall be completed within six (6) months at
15 Respondent Joseph Grasela's own expense. All remedial education shall be in addition to, and
16 shall not be credited toward, continuing education (CE) courses used for license renewal
17 purposes.

18 Failure to timely submit or complete the approved remedial education shall be considered a
19 violation of probation. The period of probation will be automatically extended until such
20 remedial education is successfully completed and written proof, in a form acceptable to the board,
21 is provided to the board or its designee.

22 Following the completion of each course, the Board or its designee may require
23 Respondent Joseph Grasela, at his own expense, to take an approved examination to test the
24 respondent's knowledge of the course. If the Respondent Joseph Grasela does not achieve a
25 passing score on the examination, this failure shall be considered a violation of probation. Any
26 such examination failure shall require respondent to take another course approved by the board in
27 the same subject area.
28

1 **22. No New Ownership of Licensed Premises**

2 Respondent Joseph Grasela shall not acquire any new ownership, legal or beneficial interest
3 nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of
4 any additional business, firm, partnership, or corporation licensed by the board. If respondent
5 currently owns or has any legal or beneficial interest in, or serves as a manager, administrator,
6 member, officer, director, trustee, associate, or partner of any business, firm, partnership, or
7 corporation currently or hereinafter licensed by the board, respondent may continue to serve in
8 such capacity or hold that interest, but only to the extent of that position or interest as of the
9 effective date of this decision. Violation of this restriction shall be considered a violation of
10 probation.

11 **23. Consultant for Owner or Pharmacist-In-Charge**

12 During the period of probation, Respondent Joseph Grasela shall not supervise any intern
13 pharmacist or serve as a consultant to any entity licensed by the Board. Respondent Joseph
14 Grasela may be a pharmacist-in-charge at Respondent UCP only. However, if during the period
15 of probation Respondent Joseph Grasela serves as a pharmacist-in-charge at Respondent UCP, he
16 shall retain an independent consultant at his own expense who shall be responsible for reviewing
17 pharmacy operations on a monthly basis for compliance by Respondents with state and federal
18 laws and regulations governing the practice of pharmacy and for compliance by Respondent
19 Joseph Grasela with the obligations of a pharmacist-in-charge. The consultant shall be a
20 pharmacist licensed by and not on probation with the Board who has expertise in compounding
21 and whose name shall be submitted to the Board or its designee, for prior approval, within thirty
22 (30) days of the effective date of this decision. Respondent Joseph Grasela shall not be a
23 pharmacist-in-charge at more than one pharmacy or at any pharmacy of which he is not the sole
24 owner. Failure to timely retain, seek approval of, or ensure timely reporting by the consultant
25 shall be considered a violation of probation.

26 During the period of probation, the Board or its designee, retains the discretion to reduce
27 the frequency of the pharmacist consultant's review of Respondent UCP's operations.
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

DATED:

JOSEPH GRASELA, as an individual and as
authorized agent on behalf of UNIVERSITY RX
SPECIALIST, DBA UNIVERSITY COMPOUNDING
PHARMACY
Respondents

DATED:

Tony J. Park, Pharm.D., J.D.
Attorney for Respondents

Dated:

STIPULATED SETTLEMENT (4347)

Exhibit A

Accusation No. 4347

1 KAMALA D. HARRIS
Attorney General of California
2 GREGORY J. SALUTE
Supervising Deputy Attorney General
3 DESIREE I. KELLOGG
Deputy Attorney General
4 State Bar No. 126461
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 645-2996
7 Facsimile: (619) 645-2061
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:

Case No. 4347

12 **UNIVERSITY RX SPECIALIST,**
13 **DBA UNIVERSITY COMPOUNDING PHARMACY**
14 **1875 3rd Avenue**
San Diego, CA 92101

**FIRST AMENDED
ACCUSATION**

15 **Pharmacy Permit No. PHY 45621**
16 **Sterile Compounding License No. LSC 99018**

17 **and**

18 **JOSEPH GRASELA**
19 **4767 Ocean Blvd., #1001**
San Diego, CA 92109

20 **Pharmacist License No. RPH 40868**

21 Respondents.

1 Complainant alleges:

2 **PARTIES**

3 1. Virginia Herold (Complainant) brings this First Amended Accusation solely in her
4 official capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer
5 Affairs.

6 2. On or about March 31, 1987, the Board of Pharmacy issued Pharmacist License No.
7 RPH 40868 to Joseph Grasela (Respondent Joseph Grasela). The Pharmacist License was in full
8 force and effect at all times relevant to the charges brought herein and will expire on November
9 30, 2016, unless renewed.

10 3. On or about August 23, 2002, the Board of Pharmacy issued Pharmacy Permit
11 Number PHY 45621 to University RX Specialist, doing business as University Compounding
12 Pharmacy (Respondent UCP) with Joseph Grasela as the President and Pharmacist-in-Charge.
13 The Pharmacy Permit was in full force and effect at all times relevant to the charges brought
14 herein and will expire on August 1, 2016, unless renewed.

15 4. On or about July 1, 2003, the Board of Pharmacy issued Sterile Compounding
16 License Number LSC 99018 to University RX Specialist, doing business as University
17 Compounding Pharmacy (Respondent University Compounding Pharmacy). The Sterile
18 Compounding License was in full force and effect at all times relevant to the charges brought
19 herein and will expire on August 1, 2016, unless renewed.

20 **JURISDICTION**

21 5. This First Amended Accusation is brought before the Board of Pharmacy (Board),
22 Department of Consumer Affairs, under the authority of the following laws. All section
23 references are to the Business and Professions Code unless otherwise indicated.

24 6. Section 4011 of the Code provides that the Board shall administer and enforce both
25 the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances
26 Act [Health & Safety Code, § 11000 et seq.].

27 7. Section 4300(a) of the Code provides that every license issued by the Board may be
28 suspended or revoked.

1 8. Section 4300.1 of the Code states:

2 The expiration, cancellation, forfeiture, or suspension of a board-issued
3 license by operation of law or by order or decision of the board or a court of law,
4 the placement of a license on a retired status, or the voluntary surrender of a
5 license by a licensee shall not deprive the board of jurisdiction to commence or
6 proceed with any investigation of, or action or disciplinary proceeding against, the
7 licensee or to render a decision suspending or revoking the license.

8 STATUTORY PROVISIONS

9 9. Section 4022 of the Code states:

10 Dangerous drug" or "dangerous device" means any drug or device unsafe for
11 self-use in humans or animals, and includes the following:

12 (a) Any drug that bears the legend: "Caution: federal law prohibits
13 dispensing without prescription," "Rx only," or words of similar import.

14 (b) Any device that bears the statement: "Caution: federal law restricts this
15 device to sale by or on the order of a _____," "Rx only," or words of similar import,
16 the blank to be filled in with the designation of the practitioner licensed to use or
17 order use of the device.

18 (c) Any other drug or device that by federal or state law can be lawfully
19 dispensed only on prescription or furnished pursuant to Section 4006.

20 10. Section 4113, subdivision (c) of the Code states: "The pharmacist-in-charge shall be
21 responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining
22 to the practice of pharmacy."

23 11. Section 4127.7 of the Code states:

24 On or after July 1, 2005, a pharmacy shall compound sterile injectable products
25 from one or more nonsterile ingredients in one of the following environments:

26 (a) An ISO class 5 laminar airflow hood within an ISO class 7 cleanroom. The
27 cleanroom must have a positive air pressure differential relative to adjacent areas.

28 (b) An ISO class 5 cleanroom.

(c) A barrier isolator that provides an ISO class 5 environment for
compounding.

12. Section 4301 of the Code states in pertinent part:

The board shall take action against any holder of a license who is guilty of
unprofessional conduct or whose license has been procured by fraud or
misrepresentation or issued by mistake. Unprofessional conduct shall include, but
is not limited to, any of the following:

.....
1
2 (j) The violation of any of the statutes of this state, or any other state, or of
3 the United States regulating controlled substances and dangerous drugs.
4

.....
5 (o) Violating or attempting to violate, directly or indirectly, or assisting in
6 or abetting the violation of or conspiring to violate any provision or term of this
7 chapter or of the applicable federal and state laws and regulations governing
8 pharmacy, including regulations established by the board or by any other state or
9 federal regulatory agency.
10

.....
11
12 13. Section 4307(a) of the Code states that:
13

14 Any person who has been denied a license or whose license has been revoked
15 or is under suspension, or who has failed to renew his or her license while it was
16 under suspension, or who has been a manager, administrator, owner member, officer,
17 director, associate, or partner of any partnership, corporation, firm, or association
18 whose application for a license has been denied or revoked, is under suspension or
19 has been placed on probation, and while acting as the manger, administrator, owner,
20 member, officer, director, associate, or partner had knowledge or knowingly
21 participated in any conduct for which the license was denied, revoked, suspended, or
22 placed on probation, shall be prohibited from serving as a manger, administrator,
23 owner, member, officer, director, associate, or partner of a licensee as follows:
24

25 (1) Where a probationary license is issued or where an existing license is placed
26 on probation, this prohibition shall remain in effect for a period not to exceed five
27 years.
28

(2) Where the license is denied or revoked, the prohibition shall continue until
the license is issued or reinstated.

14. Health and Safety Code section 110390 states:

It is unlawful for any person to disseminate any false advertisement of any
food, drug, device or cosmetic. An advertisement is false if it is false or misleading
in any particular.

15. Health and Safety Code section 110403 states in pertinent part that:

It is unlawful for any person to advertise any drug or device represented to
have any effect in any of the following conditions, disorders, or diseases:

...

(aa) sexual impotence.
...

16. Health and Safety Code section 110405 states:

An advertisement that is not unlawful under Section 110390 is not unlawful under Section 110403 if it is disseminated only to members of the medical, dental, pharmaceutical, or veterinary professions, or appears only in the scientific periodicals of these professions, or is disseminated only for the purpose of public health education by persons not commercially interested, directly or indirectly, in the sale of drugs or devices.

REGULATORY PROVISIONS

17. California Code of Regulations, title 16, section 1735(a):
states in pertinent part:

“Compounding” means any of the following activities occurring in a licensed pharmacy, by or under the supervision of a licensed pharmacist, pursuant to a prescription:

- (1) Altering the dosage form or delivery system of a drug
- (2) Altering the strength of a drug
- (3) Combining components or active ingredients
- (4) Preparing a drug product from chemicals or bulk drug substances

...

18. California Code of Regulations, title 16, section 1735.2(h) states:

....

(h) Every compounded drug product shall be given an expiration date representing the date beyond which, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used. This “beyond use date” of the compounded drug product shall not exceed 180 days from preparation or the shortest expiration date of any component in the compounded drug product, unless a longer date is supported by stability studies of finished drugs or compounded drug products using the same components and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

...

19. California Code of Regulations, title 16, section 1735.8 states:

(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies and procedures, a written quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled strength of compounded drug products.

(b) The quality assurance plan shall include written procedures for verification, monitoring, and review of the adequacy of the compounding process and shall also include written documentation of review of those processes by qualified pharmacy

personnel.

(c) The quality assurance plan shall include written standards for qualitative and quantitative integrity, potency, quality, and labeled strength analysis of compounded drug products. All qualitative and quantitative analysis reports for compounded drug products shall be retained by the pharmacy and collated with the compounding record and master formula.

(d) The quality assurance plan shall include a written procedure for scheduled action in the event any compounded drug product is ever discovered to be below minimum standards for integrity, potency, quality, or labeled strength.

20. California Code of Regulations, title 16, section 1751.7(a)(4) states:¹

(a) Any pharmacy engaged in compounding sterile injectable drug products shall maintain, as part of its written policies and procedures, a written quality assurance plan including, in addition to the elements required by section 1735.8, a documented, ongoing quality assurance program that monitors personnel performance, equipment, and facilities. The end product shall be examined on a periodic sampling basis as determined by the pharmacist-in-charge to assure that it meets required specifications. The Quality Assurance Program shall include at least the following:

(4) Written justification of the chosen expiration dates for compounded sterile injectable products.

COST RECOVERY

21. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licensee found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

DRUGS

22. Testosterone Pellets and Testosterone/Anastrozole Pellets are Schedule III controlled substances pursuant to Health and Safety Code section 11056(f)(30) and dangerous drugs pursuant to Business and Professions Code section 4022.

23. Estradiol Pellets are dangerous drugs pursuant to Business and Professions Code section 4022.

¹ California Code of Regulations, title 16, section 1751.8(a)(4), in effect at the time of the inspection, was renumbered as section 1751.7(a)(4) in 2013.

FACTUAL ALLEGATIONS

24. At all relevant times herein, Respondent Joseph Grasela was the Pharmacist-in-Charge of Respondent University Compounding Pharmacy.

25. From 2012 through the present, Respondents have compounded and sold testosterone pellets, testosterone/anastroloze pellets and estradiol pellets, sterile injectable products, for use in the treatment of symptoms arising from Andropause and Menopause for implementation in the human body.

26. On the internet in 2012, Respondents advertised and represented that their testosterone pellet therapy was "[c]onvenient and effective" and provided "continuous relief from the symptoms of Andropause," including "loss of morning erection," "stronger libido" and "stronger erections." This advertisement was disseminated to the general public.

27. On or about April 23, 2012, Respondents chose an expiration date of 365 days for the testosterone pellets compounded with a cholesterol base, rather than a stearic acid base, without possessing a written justification for the chosen expiration date or substantiated studies of finished drugs or compounded drug products which used the same components and packaging showing a longer date was supported.

28. From April 23, 2012 to the present, including after the filing of an accusation alleging a violation of Business and Professions Code section 4127.7, Respondents have and continue to compound (i.e., combined components or active ingredients) sterile injectable products, i.e., testosterone pellets, estradiol pellets and testosterone/anastrozole pellets from non-sterile ingredients, but failed to perform the compounding in either: (a) an ISO class 5 laminar airflow hood within an ISO class 7 cleanroom with a positive air pressure differential relative to the adjacent areas; (b) an ISO class 5 cleanroom or (c) a barrier isolator that provides an ISO class 5 environment for compounding.

29. In August and September 2015, the Federal Drug Administration conducted inspections of University Compounding Pharmacy and issued a Form 483 against University Compounding Pharmacy, making such observations as University Compounding Pharmacy "failed to thoroughly conduct out of specification investigations with respect to sterility failure

1 found in three different batches of drug products," University Compounding Pharmacy's "aseptic
2 processing areas are deficient regarding the system for monitoring environmental conditions,"
3 and University Compounding Pharmacy's "procedures designed to prevent microbiological
4 contamination of drug products purporting to be sterile do not include adequate validation of the
5 sterilization process."

6 FIRST CAUSE FOR DISCIPLINE

7 (Labeling Without Proper Expiration Dates for Sterile Injectable Drugs)

8 30. Respondents are subject to disciplinary action under Code section 4301(o), for
9 violating title 16, California Code of Regulations, sections 1735.2(h) and 1751.7(a)(4) in that they
10 labeled testosterone pellets, compounded in a cholesterol base with an expiration date of 365 days
11 in the future, without possessing either a written justification for that chosen expiration date or
12 substantiated studies of finished drugs or compounded drug products using the same components
13 and packaging showing a longer date was supported, as set forth in paragraphs 22 through 29,
14 which are incorporated herein by reference.

15 SECOND CAUSE FOR DISCIPLINE

16 (Failure to Compound Sterile Injectable Drugs in Authorized Environment)

17 31. Respondents are subject to disciplinary action under Code section 4301(o), for
18 violating Business and Professions Code section 4127.7 in that from April 2012 through the
19 present, they compounded sterile injectable drugs, i.e., testosterone pellets, estradiol pellets and
20 testosterone/anastroloze pellets in an environment which was not authorized by law, as set forth
21 in paragraphs 22 through 29, which are incorporated herein by reference.

22 THIRD CAUSE FOR DISCIPLINE

23 (False Advertising)

24 32. Respondents are subject to disciplinary action under Code section 4301(j), for
25 violating Health and Safety Code sections 110390 and 110403 in that Respondents represented
26 and advertised an unapproved drug therapy, as having an effect on sexual impotence to the
27 general public, as set forth in paragraphs 22 through 29, which are incorporated herein by
28 reference.

1
2 **FOURTH CAUSE FOR DISCIPLINE**

3 **(Unprofessional Conduct)**

4 33. Respondents are subject to disciplinary action under Code section 4301 for
5 unprofessional conduct in that they engaged in the activities described in paragraphs 22 through
6 29 above, which are incorporated herein by reference.

7 **OTHER MATTERS**

8 34. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number
9 PHY 45621 and Sterile Compounding License Number LSC 99018 issued to University RX
10 Specialist, doing business as University Compounding Pharmacy, they shall be prohibited from
11 serving as a manager, administrator, owner, member, officer, director, associate, or partner of a
12 licensee for five years if Pharmacy Permit Number PHY 45621 and Sterile Compounding
13 License Number LSC 99018 are placed on probation or until Pharmacy Permit Number PHY
14 45621 and Sterile Compounding License Number LSC 99018 are reinstated if they are revoked.

15 35. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit
16 Number PHY 45621 and Sterile Compounding License Number LSC 99018 issued to University
17 RX Specialist, doing business as University Compounding Pharmacy, while Joseph Grasela has
18 been an officer and owner and had knowledge of or knowingly participated in any conduct for
19 which the licensee was disciplined, Joseph Grasela shall be prohibited from serving as a
20 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for
21 five years if Pharmacy Permit Number PHY 45621 and Sterile Compounding License Number
22 LSC 99018 are placed on probation or until Pharmacy Permit Number PHY 45621 and Sterile
23 Compounding License Number LSC 99018 are reinstated if they are revoked.

24 36. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License
25 No. RPH 40868 issued to Joseph Grasela, Joseph Grasela shall be prohibited from serving as a
26 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for
27 five years if Pharmacist License Number RPH 40868 is placed on probation or until Pharmacist
28 License Number RPH 40868 is reinstated if it is revoked.

1
2 **DISCIPLINARY CONSIDERATIONS**

3 37. To determine the degree of discipline, if any, to be imposed on Respondents,
4 Complainant alleges:

5 a. On or about June 27, 2006, the Board issued Citation number CI 2005 31081
6 against University RX Specialist, dba University Compounding Pharmacy for violating California
7 Code of Regulations, title 16, sections 1716 and 1764 and Civil Code section 56.10 in that it
8 filled a prescription in an improper amount and shipped drugs to the wrong address. It paid the
9 fine on or about July 18, 2006.

10 b. On or about July 30, 2010, the Board issued Citation number CI 2009 43472
11 against University RX Specialist, dba University Compounding Pharmacy for violating California
12 Code of Regulations, title 16, section 1751.7 in that it failed to conduct end product pyrogen
13 testing on all sterile injectable products compounded for non-sterile ingredients and failed to
14 conduct end product pyrogen testing on certain stock solutions which were made of non-sterile
15 ingredients. It paid the fine on or about August 18, 2010.

16 c. On or about January 28, 2010, the Board issued Citation number CI 2008 38495
17 against Joseph Grasela for violating California Code of Regulations, title 16, section 1715 in that
18 he failed to complete a current hospital pharmacy self-assessment. He paid the fine on or about
19 December 14, 2010.

20 d. On or about July 30, 2010, the Board issued Citation number CI 2010 45194
21 against Joseph Grasela for violating California Code of Regulations, title 16, section 1751.7 in
22 that he failed to conduct end-product pyrogen testing on all sterile injectable products
23 compounded for non-sterile ingredients and failed to conduct end-product pyrogen testing on
24 certain stock solutions which were made of non-sterile ingredients. He paid the fine on or about
25 August 18, 2010.

26 **PRAYER**


27 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
28 and that following the hearing, the Board of Pharmacy issue a decision:

- 1 1. Revoking or suspending Pharmacy Permit Number PHY 45621, issued to University
2 RX Specialist, doing business as University Compounding Pharmacy;
- 3 2. Revoking or suspending Sterile Compounding License Number LSC 99018, issued to
4 University RX Specialist, doing business as University Compounding Pharmacy;
- 5 3. Revoking or suspending Pharmacist License Number RPH 40868, issued to Joseph
6 Grasela;
- 7 4. Prohibiting University RX Specialist, doing business as University Compounding
8 Pharmacy from serving as a manager, administrator, owner, member, officer, director, associate,
9 or partner of a licensee for five years if Pharmacy Permit Number PHY 45621 and Sterile
10 Compounding License Number LSC 99018 are placed on probation or until Pharmacy Permit
11 Number PHY 45621 and Sterile Compounding License Number LSC 99018 are reinstated if
12 Pharmacy Permit Number PHY 45621 and Sterile Compounding License Number LSC 99018
13 issued to University RX Specialist, doing business as University Compounding Pharmacy are
14 revoked;
- 15 5. Prohibiting Joseph Grasela from serving as a manager, administrator, owner, member,
16 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number
17 PHY 45621 and Sterile Compounding License Number LSC 99018 are placed on probation or
18 until Pharmacy Permit Number PHY 45621 and Sterile Compounding License Number LSC
19 99018 are reinstated if Pharmacy Permit Number PHY 45621 and Sterile Compounding License
20 Number LSC 99018 issued to University RX Specialist, doing business as University
21 Compounding Pharmacy are revoked;
- 22 6. Prohibiting Joseph Grasela from serving as a manager, administrator, owner,
23 member, officer, director, associate, or partner of a licensee for five years if Pharmacist License
24 Number RPH 40868 is placed on probation or until Pharmacist License Number RPH 40868 is
25 reinstated if Pharmacist License Number RPH 40868 issued to Joseph Grasela is revoked;
- 26 7. Ordering University RX Specialist, doing business as University Compounding
27 Pharmacy and Joseph Grasela to pay the Board of Pharmacy the reasonable costs of the
28

1 investigation and enforcement of this case, pursuant to Business and Professions Code section
2 125.3;

3 8. Taking such other and further action as deemed necessary and proper.
4

5 DATED: 11/20/15



VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

10 SD2012704307
11 81196205.docx
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28